关键词: 乳腺癌，Luminal A型，蒽环类药物

Abstract: [Objective] To retrospectively investigate whether the use of docetaxel or paclitaxel adding to anthracycline-based regimen can improve the DFS and OS in luminal A type early stage breast cancer patients. [Methods] From January 2006 to January 2008, there were one hundred and twenty- six patients with Luminal A type early stage breast cancer included in this retrospective study. They were separated into two group according the different chemotherapy regimens, T group 83 patients and A group 43patients. The patients’ age, tumor size, lymph node status, pathology type, DFS and OS were compared between two groups. [Results] The patients’ age, tumor size and lymph node status were no significantly different between the two group. After a median follow-up of 41.1 moths, the DFS and OS was no significantly different between the two group, T 94.0% VS A 95.3%; P=0.75, and T 95.2% VS A 97.7%; P=0.48, separately. [Conclusion] Anthracycline-based regimen is enough for Luminal A type early stage breast cancer, the use of docetaxel or paclitaxel can not improve patients DFS and OS.

Key words: breast cancer, Luminal A type, anthracycline.